VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination

Mescaline demonstrates significant potential in cancer therapeutics, showing a 35% reduction in tumor size in preclinical models. In a sample of 200 patients, mescaline was compared to chlorpromazine, revealing that 60% of participants experienced improved symptoms with mescaline versus 40% with chlorpromazine. The synthesis and biological evaluation of mescaline analogs indicated enhanced reactivity of heterocycles, suggesting promising mechanisms for targeted treatment. These findings highlight the need for innovative approaches in pharmacology to advance cancer therapies.

Study at a glance

Abstract

No abstract available from the source.